SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Doubtful businessman stands in front of a crossroad with road split in three different ways as arrows shows opposed courses. Business challenge, choosing a correct pathway. Difficult decision concept
Lung cancer
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Even before the FDA’s recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate could hit $5.9 billion in 2030. However, the asset faced a series of setbacks in 2024.
January 21, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Photo of a GLP-1 injector pen on a blue background
glp-1
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
The data suggest the high dose nearly closes the efficacy gap with Zepbound.
January 17, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Eli Lilly's world headquarters in Indianapolis
GLP-1
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.
January 3, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Alzheimer’s disease
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval in the second half of 2025.
January 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Sangamo's headquarters in Silicon Valley
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Boston, MA, USA - July 1, 2022: The main entrance to the Vertex headquarters building in Boston, Massachusetts. Vertex Pharmaceuticals is an American biotechnology company.
Approvals
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.
December 23, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Map with different syringes. Covid 19 and pandemic vaccination concept. Vector illustration
Vaccines
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight
A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ongoing legal clashes in other parts of the world.
November 20, 2024
 · 
4 min read
 · 
Nick Paul Taylor
Self-knowledge, exploration of own soul, psyche, illumination of hidden in shadow.
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.
Business
Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into significant sales, with GlobalData predicting Dupixent’s COPD revenues will top $6.5 billion within 10 years.
October 15, 2024
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: MRI images of the brain for neurological
Drug Development
Novartis’ Lutathera Radiopharma Therapy Improves Survival in Difficult-to-Treat Brain Tumors
Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not experienced further disease progression, beating the 26% benchmark established in earlier studies.
September 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Johnson & Johnson's business center in Switzerland
Drug Development
J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual disease-negativity, boosting the prospects of two key growth drivers for the company.
September 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Hands in black and white dropping a collection of pills on a pink background
Weight loss
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
September 17, 2024
 · 
4 min read
 · 
Nick Paul Taylor
illustration of hands reaching for a semaglutide injector over an image of the Earth
Policy
What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy
A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, but analysts remain dubious of the estimate.
September 11, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Futuristic Cyber Abstracy Eye Background 4K
Business
Roche and Regeneron Square Off in Lucrative Eye Disease Market
Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial growth A therapy market, as healthcare providers and patients switch from older products.
September 4, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Moderna Lays Foundations for Growth, but Can It Turn Strategy Into Execution?
The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial and structural headwinds, as the biotech looks to establish new growth drivers.
August 28, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Load More